Collegium Pharmaceutical Hits Day Low of $27.11 Amid Price Pressure

Collegium Pharmaceutical, Inc. experienced a significant decline today, with the stock dropping by 7.7% and reaching an intraday low of USD 27.11. This performance marks a stark contrast to the S&P 500, which saw a minimal change of -0.06% on the same day. Over the past week, Collegium's stock has fallen by 23.55%, and its one-month performance shows a decrease of 22.79%. Year-to-date, the stock has plummeted by 41.25%, while the S&P 500 has gained 13.26%. Despite the recent downturn, Collegium has demonstrated a robust long-term growth trajectory, with net sales increasing at an annual rate of 20.28% and operating profit rising by 26.76%. However, the company reported negative results in June 2026 after three consecutive positive quarters, which may have contributed to today's stock activity. Collegium's financial metrics indicate a challenging environment, with a weak EBIT to interest ratio of 1.55 and a return on capital employed of 22.24%. The stock is currently trading at a discount compared to its peers, reflecting its unique market position within the pharmaceuticals and biotechnology industry.